Metabolic changes in tumor cells and tumor-associated macrophages: A mutual relationship

Cancer Letters

Volumn 413, Issue , 2018, Pages 102-109

  Netea Maier, Romana T ^a   Smit, Johannes W A ^a   Netea, Mihai G ^a,b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

Cell metabolism; Immunometabolism; Tumor microenvironment; Tumor associated macrophages

Indexed keywords

ATORVASTATIN; GAMMA INTERFERON; GEMCITABINE; GLUCOSE; GLUCOSE 6 PHOSPHATE; GLUTAMINE; LIPOPOLYSACCHARIDE; METFORMIN; PYRUVIC ACID; SORAFENIB; AUTACOID;

AMINO ACID METABOLISM; ANGIOGENESIS; ARTICLE; CANCER CELL; CELL METABOLISM; CELL SHAPE; GLUCOSE METABOLISM; GLYCOLYSIS; IMMUNOCOMPETENT CELL; INFLAMMATION; LIPID METABOLISM; MALIGNANT NEOPLASM; METASTASIS; NONHUMAN; NUCLEAR REPROGRAMMING; PHENOTYPE; PRIORITY JOURNAL; THERAPY RESISTANCE; THYROID CANCER; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; TUMOR MICROENVIRONMENT; ANIMAL; CELL PROLIFERATION; ENERGY METABOLISM; HUMAN; IMMUNOLOGY; MACROPHAGE; METABOLISM; NEOPLASM; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; CELL PROLIFERATION; ENERGY METABOLISM; HUMANS; INFLAMMATION MEDIATORS; MACROPHAGES; NEOPLASMS; PHENOTYPE; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 85033449921     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2017.10.037     Document Type: Review

References (95)

1. Monjazeb, A.M., Zamora, A.E., Grossenbacher, S.K., Mirsoian, A., Sckisel, G.D., Murphy, W.J., Immunoediting and antigen loss: overcoming the achilles heel of immunotherapy with antigen non-specific therapies. Front. Oncol., 3, 2013, 197.
2. Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation. Cell 144 (2011), 646–674.
3. Colotta, F., Allavena, P., Sica, A., Garlanda, C., Mantovani, A., Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 30 (2009), 1073–1081.
4. Qian, B.Z., Pollard, J.W., Macrophage diversity enhances tumor progression and metastasis. Cell 141 (2010), 39–51.
5. Joyce, J.A., Pollard, J.W., Microenvironmental regulation of metastasis. Nat. Rev. Cancer 9 (2009), 239–252.
6. Ryder, M., Ghossein, R.A., Ricarte-Filho, J.C., Knauf, J.A., Fagin, J.A., Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer. Endocr. Relat. Cancer 15 (2008), 1069–1074.
7. Caillou, B., Talbot, M., Weyemi, U., Pioche-Durieu, C., Al Ghuzlan, A., Bidart, J.M., et al. Tumor-associated macrophages (TAMs) form an interconnected cellular supportive network in anaplastic thyroid carcinoma. PloS One, 6, 2011, e22567.
8. Nonomura, N., Takayama, H., Nakayama, M., Nakai, Y., Kawashima, A., Mukai, M., et al. Infiltration of tumour-associated macrophages in prostate biopsy specimens is predictive of disease progression after hormonal therapy for prostate cancer. BJU Int. 107 (2011), 1918–1922.
9. Asgharzadeh, S., Salo, J.A., Ji, L., Oberthuer, A., Fischer, M., Berthold, F., et al. Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 30 (2012), 3525–3532.
10. Cunha, L.L., Morari, E.C., Guihen, A.C., Razolli, D., Gerhard, R., Nonogaki, S., et al. Infiltration of a mixture of immune cells may be related to good prognosis in patients with differentiated thyroid carcinoma. Clin. Endocrinol. 77 (2012), 918–925.
11. Grogg, K.L., Lohse, C.M., Pankratz, V.S., Halling, K.C., Smyrk, T.C., Lymphocyte-rich gastric cancer: associations with Epstein-Barr virus, microsatellite instability, histology, and survival. Mod. Pathol. Off. J. U. S. Can. Acad. Pathol, Inc 16 (2003), 641–651.
12. Biswas, S.K., Chittezhath, M., Shalova, I.N., Lim, J.Y., Macrophage polarization and plasticity in health and disease. Immunol. Res. 53 (2012), 11–24.
13. Mantovani, A., Biswas, S.K., Galdiero, M.R., Sica, A., Locati, M., Macrophage plasticity and polarization in tissue repair and remodelling. J. Pathol. 229 (2013), 176–185.
14. Biswas, S.K., Mantovani, A., Orchestration of metabolism by macrophages. Cell metab. 15 (2012), 432–437.
15. Carmona-Fontaine, C., Bucci, V., Akkari, L., Deforet, M., Joyce, J.A., Xavier, J.B., Emergence of spatial structure in the tumor microenvironment due to the Warburg effect. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 19402–19407.
16. Kareva, I., Hahnfeldt, P., The emerging “hallmarks” of metabolic reprogramming and immune evasion: distinct or linked?. Cancer Res. 73 (2013), 2737–2742.
17. Warburg, O., On the origin of cancer cells. Science 123 (1956), 309–314.
18. Gatenby, R.A., Gillies, R.J., Glycolysis in cancer: a potential target for therapy. Int. J. Biochem. Cell Biol. 39 (2007), 1358–1366.
19. Gatenby, R.A., Gillies, R.J., Why do cancers have high aerobic glycolysis?. Nat. Rev. Cancer 4 (2004), 891–899.
20. Pavlova, N.N., Thompson, C.B., The emerging hallmarks of cancer metabolism. Cell Metab. 23 (2016), 27–47.
21. Kunkel, M., Reichert, T.E., Benz, P., Lehr, H.A., Jeong, J.H., Wieand, S., et al. Overexpression of Glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma. Cancer 97 (2003), 1015–1024.
22. Pinheiro, C., Sousa, B., Albergaria, A., Paredes, J., Dufloth, R., Vieira, D., et al. GLUT1 and CAIX expression profiles in breast cancer correlate with adverse prognostic factors and MCT1 overexpression. Histol Histopathol. 26 (2011), 1279–1286.
23. Colegio, O.R., Chu, N.Q., Szabo, A.L., Chu, T., Rhebergen, A.M., Jairam, V., et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature 513 (2014), 559–563.
24. Arts, R.J., Plantinga, T.S., Tuit, S., Ulas, T., Heinhuis, B., Tesselaar, M., et al. Transcriptional and metabolic reprogramming induce an inflammatory phenotype in non-medullary thyroid carcinoma-induced macrophages. Oncoimmunology, 5, 2016, e1229725.
25. Gabrilovich, D.I., Nagaraj, S., Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9 (2009), 162–174.
26. Corzo, C.A., Condamine, T., Lu, L., Cotter, M.J., Youn, J.I., Cheng, P., et al. HIF-1alpha regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J. Exp. Med. 207 (2010), 2439–2453.
27. O'Neill, L.A., Kishton, R.J., Rathmell, J., A guide to immunometabolism for immunologists. Nat. Rev. Immunol. 16 (2016), 553–565.
28. Fernie, A.R., Carrari, F., Sweetlove, L.J., Respiratory metabolism: glycolysis, the TCA cycle and mitochondrial electron transport. Curr. Opin. Plant Biol. 7 (2004), 254–261.
29. Owen, O.E., Kalhan, S.C., Hanson, R.W., The key role of anaplerosis and cataplerosis for citric acid cycle function. J. Biol. Chem. 277 (2002), 30409–30412.
30. Patra, K.C., Hay, N., The pentose phosphate pathway and cancer. Trends Biochem. Sci. 39 (2014), 347–354.
31. Houten, S.M., Wanders, R.J., A general introduction to the biochemistry of mitochondrial fatty acid beta-oxidation. J. Inherit. Metab. Dis. 33 (2010), 469–477.
32. Beloribi-Djefaflia, S., Vasseur, S., Guillaumond, F., Lipid metabolic reprogramming in cancer cells. Oncogenesis, 5, 2016 e189.
33. Gazi, E., Gardner, P., Lockyer, N.P., Hart, C.A., Brown, M.D., Clarke, N.W., Direct evidence of lipid translocation between adipocytes and prostate cancer cells with imaging FTIR microspectroscopy. J. Lipid Res. 48 (2007), 1846–1856.
34. Nieman, K.M., Kenny, H.A., Penicka, C.V., Ladanyi, A., Buell-Gutbrod, R., Zillhardt, M.R., et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat. Med. 17 (2011), 1498–1503.
35. Wang, D., Dubois, R.N., Eicosanoids and cancer. Nat. Rev. Cancer 10 (2010), 181–193.
36. Xiang, X., Poliakov, A., Liu, C., Liu, Y., Deng, Z.B., Wang, J., et al. Induction of myeloid-derived suppressor cells by tumor exosomes. J. Int. Cancer 124 (2009), 2621–2633.
37. Sinha, P., Clements, V.K., Fulton, A.M., Ostrand-Rosenberg, S., Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res. 67 (2007), 4507–4513.
38. Heusinkveld, M., de Vos van Steenwijk, P.J., Goedemans, R., Ramwadhdoebe, T.H., Gorter, A., Welters, M.J., et al. M2 macrophages induced by prostaglandin E2 and IL-6 from cervical carcinoma are switched to activated M1 macrophages by CD4+ Th1 cells. J. Immunol. 187 (2011), 1157–1165.
39. Moore, G.Y., Pidgeon, G.P., Cross-talk between cancer cells and the tumour microenvironment: the role of the 5-lipoxygenase pathway. Int. J. Mol. Sci., 18, 2017.
40. Wen, Z., Liu, H., Li, M., Li, B., Gao, W., Shao, Q., et al. Increased metabolites of 5-lipoxygenase from hypoxic ovarian cancer cells promote tumor-associated macrophage infiltration. Oncogene 34 (2015), 1241–1252.
41. Xue, J., Schmidt, S.V., Sander, J., Draffehn, A., Krebs, W., Quester, I., et al. Transcriptome-based network analysis reveals a spectrum model of human macrophage activation. Immunity 40 (2014), 274–288.
42. Schumann, T., Adhikary, T., Wortmann, A., Finkernagel, F., Lieber, S., Schnitzer, E., et al. Deregulation of PPARbeta/delta target genes in tumor-associated macrophages by fatty acid ligands in the ovarian cancer microenvironment. Oncotarget 6 (2015), 13416–13433.
43. Grassian, A.R., Metallo, C.M., Coloff, J.L., Stephanopoulos, G., Brugge, J.S., Erk regulation of pyruvate dehydrogenase flux through PDK4 modulates cell proliferation. Genes Dev. 25 (2011), 1716–1733.
44. Mills, C.D., M1 and M2 macrophages: oracles of health and disease. Crit. Rev. Immunol. 32 (2012), 463–488.
45. Laoui, D., Movahedi, K., Van Overmeire, E., Van den Bossche, J., Schouppe, E., Mommer, C., et al. Tumor-associated macrophages in breast cancer: distinct subsets, distinct functions. Int. J. Dev. Biol. 55 (2011), 861–867.
46. Van Overmeire, E., Laoui, D., Keirsse, J., Van Ginderachter, J.A., Sarukhan, A., Mechanisms driving macrophage diversity and specialization in distinct tumor microenvironments and parallelisms with other tissues. Front. Immunol., 5, 2014, 127.
47. Murray, P.J., Allen, J.E., Biswas, S.K., Fisher, E.A., Gilroy, D.W., Goerdt, S., et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity 41 (2014), 14–20.
48. Mills, E.L., O'Neill, L.A., Reprogramming mitochondrial metabolism in macrophages as an anti-inflammatory signal. Eur. J. Immunol. 46 (2016), 13–21.
49. Modolell, M., Corraliza, I.M., Link, F., Soler, G., Eichmann, K., Reciprocal regulation of the nitric oxide synthase/arginase balance in mouse bone marrow-derived macrophages by TH1 and TH2 cytokines. Eur. J. Immunol. 25 (1995), 1101–1104.
50. Hu, X., Liu, G., Hou, Y., Shi, J., Zhu, L., Jin, D., et al. Induction of M2-like macrophages in recipient NOD-scid mice by allogeneic donor CD4(+)CD25(+) regulatory T cells. Cell. Mol. Immunol. 9 (2012), 464–472.
51. Van Dyken, S.J., Locksley, R.M., Interleukin-4- and interleukin-13-mediated alternatively activated macrophages: roles in homeostasis and disease. Annu. Rev. Immunol. 31 (2013), 317–343.
52. Liu, D., Chang, C., Lu, N., Wang, X., Lu, Q., Ren, X., et al. Comprehensive proteomics analysis reveals metabolic reprogramming of tumor-associated macrophages stimulated by the tumor microenvironment. J. Proteome Res. 16 (2017), 288–297.
53. Penny, H.L., Sieow, J.L., Adriani, G., Yeap, W.H., See Chi Ee, P., San Luis, B., et al. Warburg metabolism in tumor-conditioned macrophages promotes metastasis in human pancreatic ductal adenocarcinoma. Oncoimmunology, 5, 2016, e1191731.
54. Wenes, M., Shang, M., Di Matteo, M., Goveia, J., Martin-Perez, R., et al. Macrophage metabolism controls tumor blood vessel morphogenesis and metastasis. Cell Metab. 24 (2016), 701–715.
55. Tannahill, G.M., Curtis, A.M., Adamik, J., Palsson-McDermott, E.M., McGettrick, A.F., et al. Succinate is an inflammatory signal that induces IL-1beta through HIF-1alpha. Nature 496 (2013), 238–242.
56. Zhang, D., Li, J., Wang, F., Hu, J., Wang, S., Sun, Y., 2-Deoxy-D-glucose targeting of glucose metabolism in cancer cells as a potential therapy. Cancer Lett. 355 (2014), 176–183.
57. Mustafa, E.H., Mahmoud, H.T., Al-Hudhud, M.Y., Abdalla, M.Y., Ahmad, I.M., Yasin, S.R., et al. 2-deoxy-D-Glucose synergizes with doxorubicin or L-buthionine sulfoximine to reduce adhesion and migration of breast cancer cells. Asian Pac. J. Cancer Prev. APJCP 16 (2015), 3213–3222.
58. Wang, Z., Zhang, L., Zhang, D., Sun, R., Wang, Q., Liu, X., Glycolysis inhibitor 2-deoxy-D-glucose suppresses carcinogen-induced rat hepatocarcinogenesis by restricting cancer cell metabolism. Mol. Med. Rep. 11 (2015), 1917–1924.
59. Sobhakumari, A., Orcutt, K.P., Love-Homan, L., Kowalski, C.E., Parsons, A.D., Knudson, C.M., et al. 2-Deoxy-d-glucose suppresses the in vivo antitumor efficacy of erlotinib in head and neck squamous cell carcinoma cells. Oncol. Res. 24 (2016), 55–64.
60. Huang, C.C., Wang, S.Y., Lin, L.L., Wang, P.W., Chen, T.Y., Hsu, W.M., et al. Glycolytic inhibitor 2-deoxyglucose simultaneously targets cancer and endothelial cells to suppress neuroblastoma growth in mice. Dis. Models Mech. 8 (2015), 1247–1254.
61. Tomizawa, M., Shinozaki, F., Motoyoshi, Y., Sugiyama, T., Yamamoto, S., Ishige, N., 2-Deoxyglucose and sorafenib synergistically suppress the proliferation and motility of hepatocellular carcinoma cells. Oncol. Lett. 13 (2017), 800–804.
62. Wokoun, U., Hellriegel, M., Emons, G., Grundker, C., Co-treatment of breast cancer cells with pharmacologic doses of 2-deoxy-D-glucose and metformin: starving tumors. Oncol. Rep. 37 (2017), 2418–2424.
63. Reyes, R., Wani, N.A., Ghoshal, K., Jacob, S.T., Motiwala, T., Sorafenib and 2-deoxyglucose synergistically inhibit proliferation of both sorafenib-sensitive and -resistant HCC cells by inhibiting ATP production. Gene Expr. 17 (2017), 129–140.
64. Dwarakanath, B.S., Singh, D., Banerji, A.K., Sarin, R., Venkataramana, N.K., Jalali, R., et al. Clinical studies for improving radiotherapy with 2-deoxy-D-glucose: present status and future prospects. J. Cancer Res. Ther. 5:Suppl 1 (2009), S21–S26.
65. Poczobutt, J.M., De, S., Yadav, V.K., Nguyen, T.T., Li, H., Sippel, T.R., et al. Expression profiling of macrophages reveals multiple populations with distinct biological roles in an immunocompetent orthotopic model of lung cancer. J. Immunol. 196 (2016), 2847–2859.
66. Nakao, S., Kuwano, T., Tsutsumi-Miyahara, C., Ueda, S., Kimura, Y.N., Hamano, S., et al. Infiltration of COX-2-expressing macrophages is a prerequisite for IL-1 beta-induced neovascularization and tumor growth. J. Clin. investigation 115 (2005), 2979–2991.
67. Bianchini, F., Massi, D., Marconi, C., Franchi, A., Baroni, G., Santucci, M., et al. Expression of cyclo-oxygenase-2 in macrophages associated with cutaneous melanoma at different stages of progression. Prostagl. Other Lipid Mediat. 83 (2007), 320–328.
68. Daurkin, I., Eruslanov, E., Stoffs, T., Perrin, G.Q., Algood, C., Gilbert, S.M., et al. Tumor-associated macrophages mediate immunosuppression in the renal cancer microenvironment by activating the 15-lipoxygenase-2 pathway. Cancer Res. 71 (2011), 6400–6409.
69. Schlager, S.I., Madden, L.D., Meltzer, M.S., Bara, S., Mamula, M.J., Role of macrophage lipids in regulating tumoricidal activity. Cell. Immunol. 77 (1983), 52–68.
70. Rao, E., Singh, P., Zhai, X., Li, Y., Zhu, G., Zhang, Y., et al. Inhibition of tumor growth by a newly-identified activator for epidermal fatty acid binding protein. Oncotarget 6 (2015), 7815–7827.
71. Zhang, Y., Sun, Y., Rao, E., Yan, F., Li, Q., Zhang, Y., et al. Fatty acid-binding protein E-FABP restricts tumor growth by promoting IFN-beta responses in tumor-associated macrophages. Cancer Res. 74 (2014), 2986–2998.
72. Jha, A.K., Huang, S.C., Sergushichev, A., Lampropoulou, V., Ivanova, Y., Loginicheva, E., et al. Network integration of parallel metabolic and transcriptional data reveals metabolic modules that regulate macrophage polarization. Immunity 42 (2015), 419–430.
73. Choi, J., Stradmann-Bellinghausen, B., Yakubov, E., Savaskan, N.E., Regnier-Vigouroux, A., Glioblastoma cells induce differential glutamatergic gene expressions in human tumor-associated microglia/macrophages and monocyte-derived macrophages. Cancer Biol. Ther. 16 (2015), 1205–1213.
74. Clementi, E., Brown, G.C., Feelisch, M., Moncada, S., Persistent inhibition of cell respiration by nitric oxide: crucial role of S-nitrosylation of mitochondrial complex I and protective action of glutathione. Proc. Natl. Acad. Sci. U. S. A. 95 (1998), 7631–7636.
75. Albina, J.E., Mastrofrancesco, B., Modulation of glucose metabolism in macrophages by products of nitric oxide synthase. Am. J. Physiol. 264 (1993), C1594–C1599.
76. Rath, M., Muller, I., Kropf, P., Closs, E.I., Munder, M., Metabolism via arginase or nitric oxide synthase: two competing arginine pathways in macrophages. Front. Immunol., 5, 2014, 532.
77. MacMicking, J., Xie, Q.W., Nathan, C., Nitric oxide and macrophage function. Annu. Rev. Immunol. 15 (1997), 323–350.
78. Klimp, A.H., Hollema, H., Kempinga, C., van der Zee, A.G., de Vries, E.G., Daemen, T., Expression of cyclooxygenase-2 and inducible nitric oxide synthase in human ovarian tumors and tumor-associated macrophages. Cancer Res. 61 (2001), 7305–7309.
79. Dinapoli, M.R., Calderon, C.L., Lopez, D.M., The altered tumoricidal capacity of macrophages isolated from tumor-bearing mice is related to reduce expression of the inducible nitric oxide synthase gene. J. Exp. Med. 183 (1996), 1323–1329.
80. Biswas, S.K., Gangi, L., Paul, S., Schioppa, T., Saccani, A., Sironi, M., et al. A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). Blood 107 (2006), 2112–2122.
81. Ghassabeh, G.H., De Baetselier, P., Brys, L., Noel, W., Van Ginderachter, J.A., et al. Identification of a common gene signature for type II cytokine-associated myeloid cells elicited in vivo in different pathologic conditions. Blood 108 (2006), 575–583.
82. Sharda, D.R., Yu, S., Ray, M., Squadrito, M.L., De Palma, M., Wynn, T.A., et al. Regulation of macrophage arginase expression and tumor growth by the Ron receptor tyrosine kinase. J. Immunol. 187 (2011), 2181–2192.
83. Wu, T., Sun, C., Chen, Z., Zhen, Y., Peng, J., Qi, Z., et al. Smad3-deficient CD11b(+)Gr1(+) myeloid-derived suppressor cells prevent allograft rejection via the nitric oxide pathway. J. Immunol. 189 (2012), 4989–5000.
84. Casazza, A., Laoui, D., Wenes, M., Rizzolio, S., Bassani, N., Mambretti, M., et al. Impeding macrophage entry into hypoxic tumor areas by Sema3A/Nrp1 signaling blockade inhibits angiogenesis and restores antitumor immunity. Cancer Cell 24 (2013), 695–709.
85. Henze, A.T., Mazzone, M., The impact of hypoxia on tumor-associated macrophages. J. Clin. Investig. 126 (2016), 3672–3679.
86. Barar, J., Omidi, Y., Dysregulated pH in tumor microenvironment checkmates cancer therapy. BioImpacts BI 3 (2013), 149–162.
87. Zitvogel, L., Pietrocola, F., Kroemer, G., Nutrition, inflammation and cancer. Nat. Immunol. 18 (2017), 843–850.
88. Husain, Z., Huang, Y., Seth, P., Sukhatme, V.P., Tumor-derived lactate modifies antitumor immune response: effect on myeloid-derived suppressor cells and NK cells. J. Immunol. 191 (2013), 1486–1495.
89. Zhang, H.L., Wang, M.D., Zhou, X., Qin, C.J., Fu, G.B., Tang, L., et al. Blocking preferential glucose uptake sensitizes liver tumor-initiating cells to glucose restriction and sorafenib treatment. Cancer Lett. 388 (2017), 1–11.
90. Jiang, Q., Weiss, J.M., Back, T., Chan, T., Ortaldo, J.R., Guichard, S., et al. mTOR kinase inhibitor AZD8055 enhances the immunotherapeutic activity of an agonist CD40 antibody in cancer treatment. Cancer Res. 71 (2011), 4074–4084.
91. Karnevi, E., Andersson, R., Rosendahl, A.H., Tumour-educated macrophages display a mixed polarisation and enhance pancreatic cancer cell invasion. Immunol. Cell Biol. 92 (2014), 543–552.
92. Ding, L., Liang, G., Yao, Z., Zhang, J., Liu, R., Chen, H., et al. Metformin prevents cancer metastasis by inhibiting M2-like polarization of tumor associated macrophages. Oncotarget 6 (2015), 36441–36455.
93. Chiang, C.F., Chao, T.T., Su, Y.F., Hsu, C.C., Chien, C.Y., Chiu, K.C., et al. Metformin-treated cancer cells modulate macrophage polarization through AMPK-NF-kappaB signaling. Oncotarget 8 (2017), 20706–20718.
94. Chang, C.H., Qiu, J., O'Sullivan, D., Buck, M.D., Noguchi, T., Curtis, J.D., et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell 162 (2015), 1229–1241.
95. Liu, Q., Li, Y., Niu, Z., Zong, Y., Wang, M., Yao, L., et al. Atorvastatin (Lipitor) attenuates the effects of aspirin on pancreatic cancerogenesis and the chemotherapeutic efficacy of gemcitabine on pancreatic cancer by promoting M2 polarized tumor associated macrophages. J. Exp. Clin. Cancer Res. CR, 35, 2016, 33.